Clinical Trial Detail

NCT ID NCT03430518
Title Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Amy Tiersten
Indications

Her2-receptor negative breast cancer

ovary epithelial cancer

Therapies

Durvalumab + Eribulin

Age Groups: adult senior

Additional content available in CKB BOOST